|
ER-
| | | | | | |
|---|
|
Pathway
|
nG
|
nE
|
fE
|
Pval(signif)
|
fconsE
|
Pval(consist)
|
|---|
|
MYC
|
76
|
472
|
0.17
|
< 0.001
|
0.88
|
< 0.001
|
|
E2F3
|
104
|
793
|
0.15
|
< 0.001
|
0.58
|
< 0.001
|
|
RAS
|
135
|
1387
|
0.15
|
< 0.001
|
0.63
|
< 0.001
|
|
ERBB2
|
228
|
4223
|
0.16
|
< 0.001
|
0.84
|
< 0.001
|
|
EGFR
|
180
|
2395
|
0.15
|
< 0.001
|
0.66
|
< 0.001
|
|
AKT
|
41
|
346
|
0.42
|
< 0.001
|
1.00
|
< 0.001
|
|
IL12
|
17
|
38
|
0.28
|
< 0.001
|
0.95
|
< 0.001
|
|
IL4
|
11
|
9
|
0.16
|
0.11
|
1.00
|
< 0.001
|
|
IL2
|
19
|
22
|
0.13
|
0.19
|
0.73
|
0.009
|
|
IL13
|
7
|
6
|
0.29
|
0.01
|
1.00
|
< 0.001
|
|
INFG
|
40
|
222
|
0.28
|
< 0.001
|
0.90
|
< 0.001
|
|
TGFB
|
62
|
479
|
0.25
|
< 0.001
|
0.92
|
< 0.001
|
|
ER+
| | | | | | |
|
Pathway
|
nG
|
nE
|
fE
|
Pval(signif)
|
fconsE
|
Pval(consist)
|
|
MYC
|
76
|
749
|
0.26
|
0.24
|
0.79
|
< 0.001
|
|
E2F3
|
104
|
1285
|
0.24
|
0.58
|
0.57
|
< 0.001
|
|
RAS
|
135
|
2231
|
0.25
|
0.48
|
0.57
|
< 0.001
|
|
ERBB2
|
228
|
7336
|
0.28
|
0.01
|
0.74
|
< 0.001
|
|
EGFR
|
180
|
4286
|
0.27
|
0.13
|
0.66
|
< 0.001
|
|
AKT
|
41
|
676
|
0.82
|
< 0.001
|
1.00
|
< 0.001
|
|
IL12
|
17
|
32
|
0.23
|
0.53
|
0.97
|
< 0.001
|
|
IL4
|
11
|
10
|
0.18
|
0.72
|
0.70
|
0.06
|
|
IL2
|
19
|
40
|
0.23
|
0.51
|
0.60
|
0.08
|
|
IL13
|
7
|
6
|
0.29
|
0.28
|
0.50
|
0.35
|
|
INFG
|
40
|
284
|
0.36
|
0.003
|
0.83
|
< 0.001
|
|
TGFB
|
62
|
713
|
0.38
|
< 0.001
|
0.86
|
< 0.001
|
- Properties of the inferred relevance expression correlation networks in ER- and ER+ breast cancer. For each molecular pathway we give the number of pathway genes present in the expression matrix (nG), the number and fraction of edges (i.e significant pairwise correlations between genes) (nE & fE), the significance of the average connectivity of the network (Pval(signif)), the fraction of edges that are consistent with the prior in-vitro information (fconsE), the corresponding p-value of significance (Pval(consist)). P-values were estimated using 1000 permutations.
